Tell us about your exciting accomplishments!

OVPR staff is excited about the breakthroughs in research and scholarly accomplishments on our campus. If you have been awarded a grant, submitted a paper for publication or been notified that your research is being published in a scholarly journal, please contact us at so we can share the news with the rest of the OUHSC research community.

"The ORA submission process: A review for new investigators"
New PI Training 04-20-16 Final

Other helpful information

On this page, you will also find useful Institutional Data that you may be asked to provide when submitting a proposal.   Please let us know if there is additional information or links you would like to see on our site. Simply complete our Suggestion Form.

ORA Research News - Monday, October 8, 2018

PHF Bridge Grant PROGRAM

Proposal Deadline: Friday, November 16, 2018

The primary objective of the PHF Bridge Grant program is to provide funding of limited duration to

enhance OUHSC faculty competitiveness for NIH R01 and Department of Defense (DoD) extramural

funding.  PHF Bridge Grant funding is specifically for those OUHSC faculty members who have

submitted R01 applications to NIH or applications to DoD that have been reviewed and scored,

but not funded.   Applicants may request support of up to $75,000 for one year.

Guidelines and Application Form is attached or go to: Grant-Guidelines - Final - November 2018.docx?ver=2018-10-08-074830-023


20th Annual U.S. Department of Health and Human Services SBIR/STTR Conference

A Better Tomorrow: Big Ideas in Biotech – October 30, 2018 through November 1, 2018 in Dallas, TX.

For additional information go to:



Second Annual Symposium on Neonatal Resuscitation Friday, October 12, 2018 is the

Samis Education Center.  For additional information see the attached document. Neonatal Resuscitation Symposium Brochure2.pdf?ver=2018-10-08-074829-697


2019 Annual Cancer Research Symposium | Registration & Call for Abstracts

Abstracts due Friday, November 16, 2018.  Conference is Friday, February 1, 2019. 

See attached document for additional information. Research Symposium.docx?ver=2018-10-08-074829-697


Beginning Grantwriting Workshop will be held on Friday, November 9, 9:00 am to 12:00 pm

at 840 Research Parkway, Suite 400, in Oklahoma City. Research Park is off Lincoln Blvd. between

4th and 8th street. The content of Beginning Grantwriting is how to plan a grant proposal, how to

gather information for the plan, and how to schedule your writing time. Tips for good writing will be


Grant Resources Searching Workshop will be held on the same day, Friday, November 9,

1:00 pm to 3:00 pm, in the same room. Grant Resources Searching will cover how to search for

Foundation Grants and how to search for Federal Grants. Bring your laptop and search in class.

Lunch will be on your own. There are 2 restaurants in an adjacent building. There is no fee, but

you must register. Send an email with your name, your college or university affiliation, and position




ABSTRACT DEADLINE EXTENDED! Harold Hamm Diabetes Center (HHDC) Research


Abstract submission for the 2018 HHDC 2018 Research Symposium has been extended to Wednesday,

October 10th. Abstracts must be received by 5 p.m. The 2018 HHDC Research Symposium will be

held on Friday, November 16, 2018 at the Samis Education Center in Children’s Hospital in Oklahoma

City. The Symposium will consist of selected oral presentations, a poster session, and Symposia talks

by Silvia Corvera, MD, Professor, University of Massachusetts Medical School, Timothy McGraw, PhD,

Professor, Cornell Weill College of Medicine and Morris White, PhD, Professor, Harvard University. 

For abstract submission guidelines and to RSVP for this free event, please go to:  Please contact 

with any questions for this event.



ORAU-Directed Research and Development (ODRD) Program

The FY 2019 competition for collaborative awards of up to $75,000 to be shared between the university

and ORAU researchers is now open. We anticipate and expect that these seed funds will position the

collaborative teams to be more competitive for new, external funding opportunities. The deadline for

joint ORAU/university proposals is March 25, 2019 and potential university partners are encouraged

to submit concepts for discussion with ORAU partners as soon as possible.





Proposal Deadline: Friday, October 26, 2018

The Presbyterian Health Foundation (PHF) Three-Dimensional (3D) Bio-Printing Seed Grant Program

will support projects that utilize new and innovative 3D bio-printing technologies aimed at revolutionizing

medical practice, drug discovery processes, and the study of the fundamental mechanisms of disease. 

The overall goal of this program is to provide a one-year grant for OUHSC investigators to initiate

research programs utilizing the new 3D BioAssemblyBot® (Advanced Solutions) bio-printer,

website:  Additional information about basic supplies

can be on found on

Applicants may request support of up to $40,000 for one year. Guidelines and Application Form are

attached or go to: 3D Bio-printing Seed Grant-Guidelines - Final - 2018.docx?ver=2018-10-08-074850-667


Grants and Contracts Newsletter for September 2018 is attached. News September 2018.pdf?ver=2018-10-08-074913-480


Association of American Medical Colleges (AAMC) - FOCI Community,

You have likely been following discussions at your institution and in the national press about disclosure

and transparency issues in light of the recent resignation of Memorial Sloan Kettering Cancer Center’s

Chief Medical Officer, Dr. José Baselga, following a New York Times article about his failure to disclose

industry ties in a large number of publications. The attached memorandum discusses some of the

background, related AAMC activities, and some immediate steps you can take to communicate with

your faculty about this situation and our shared obligation to facilitate the disclosure of timely, accurate,

and complete information about academic medicine’s relationships with industry.

This is the beginning of a much larger conversation in which all of you are engaged at your institutions

and with the AAMC, and we are grateful for the work of this group. With the assistance of the FOCI

Steering Committee leadership and the collaboration of partners across the AAMC membership and

broader research community, we will ensure that you are kept informed about new developments and

involved in these critical issues. Ross McKinney, Chief Scientific Officer, and I are always available to

you for questions or comments, so do not hesitate to reach out to us or to others in this group.

Heather H. Pierce, JD, MPH

Senior Director, Science Policy

Regulatory Counsel, Scientific Affairs

Association of American Medical Colleges

655 K Street NW, Suite 100

Washington, DC 20001

T: 202-478-9926  E:   

For additional information see the attached document. to FOCI on COI Issues Sept 2018.pdf?ver=2018-10-08-074925-713




Notice of Intent to Publish a Funding Opportunity Announcement for Specialized Centers of Research

Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional) (NOT-OD-18-232)


Notice Regarding 2018 Bayh-Dole Act Final Rule - Rights to Federally Funded Inventions and

Licensing of Government Owned Inventions (NOT-OD-18-233)


Update on NIH Extension Policy for Early Stage Investigator Status (ESI) (NOT-OD-18-235)


Notice of Change to Instructions for Application Submission for PAR-18-324 "Testing Interventions

for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)" (NOT-OD-18-236)


Notice of Participation of the National Institute on Aging (NIA) in RFA-MH-19-510 "Novel Mechanism

Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)"



Notice of Participation of the National Institute on Aging (NIA) in RFA-MH-19-511 "Novel Mechanism

Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)"



Request for Information (RFI) on the NIH Back Pain Consortium (BACPAC) Research Program



Notice of Upcoming Webinar for the NIH Back Pain Consortium (BACPAC) Research Program



Notice of Pre-Application Webinars for RFA-AR-17-002, "NIAMS Core Centers for Clinical Research

(CCCR) (P30)" (NOT-AR-19-030)


Notice of a Pre-Application Webinar for RFA-CA-18-029, Cancer Prevention Clinical Trials Network

(CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required) (NOT-CA-18-111)


Notice of a Pre-Application Webinar for RFA-CA-18-030, Cancer Prevention Clinical Trials Network

(CP-CTNet): Data Management, Auditing, and Coordinating Center (DMACC)(U24 Clinical Trial Required)



Pre-Application Webinar and Frequently Asked Questions (FAQ) for RFA-CA-18-018 Prevention of

HPV-related Cancers in HIV-Infected individuals: United States-Latin American-Caribbean Clinical Trials

Network: Partnership Centers (U54) (NOT-CA-18-113)


Notice of Clarification to Additional Information on Eligibility and Number of Applications in Funding

Opportunity Announcement (FOA) PAR-18-880, "NCI Outstanding Investigator Award (R35 Clinical

Trial Not Allowed)" (NOT-CA-18-114)


Notice of NIDA's participation in PAR-18-930 "Development and Optimization of Tasks and Measures

for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)" (NOT-DA-18-039)


Notice of Change to the Open Date in PA-18-917, " Developing the Therapeutic Potential of the

Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional) (NOT-DA-18-044)


Notice of Correction to Eligibility Information for RFA-DA-19-017 "HEALing Communities Study:

Developing and Testing an Integrated Approach to Address the Opioid Crisis (Data Coordinating

Center) (UM1- Clinical Trials Not Allowed)" (NOT-DA-18-045)


Notice of Clarification of Award Budget for RFA-DE-19-004 Encouraging Development of Novel

Amelogenesis Models (UG3/UH3 Clinical Trial Not Allowed) (NOT-DE-18-021)


Notice of Correction to Eligibility in RFA-DE-19-005, NIDCR Award for Sustaining Outstanding

Achievement in Research (SOAR) (R35, Clinical Trials Not Allowed) (NOT-DE-18-022)


Vet-LIRN Network Capacity-Building Projects (NOT-FD-18-017)


Minor Use Minor Species Development of Drugs (R01) (NOT-FD-18-018)


Notice of Clarification about Classification of Pre-Doctoral Students for RFA-MD-18-007, NIMHD

Minority Health and Health Disparities Research Training (MHRT) Program (T37) (NOT-MD-18-017)


Notice of Correction of PAR-18-269 "Products to Support Applied Research Towards Zero Suicide

Healthcare Systems (R43/R44 Clinical Trial Optional)" (NOT-MH-18-052)


Announcement of the NCATS Rare Diseases Are Not Rare! Challenge (NOT-TR-19-002)



Please Note:  When only one application is allowed per Institution according to the sponsor

instructions, a one-page letter of intent summarizing the proposed project should be submitted

to the Vice President for Research at least one month prior to the application deadline (unless

otherwise noted).  The letters of intent will be reviewed and a single application will be chosen  

for submission from the University.




The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional) (RFA-DA-19-008)

Deadline December 14, 2018


Computational Approaches for Validating Dimensional Constructs of Relevance to Psychopathology

(R01 Clinical Trial Optional) (RFA-MH-19-242) – Deadline January 3, 2019


Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training,

and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program

(Admin Suppl - Clinical Trial Not Allowed) (PA-18-934) – Deadline December 17, 2018


NIH Administrative Supplements to Recover Losses Due to Hurricanes Harvey, Irma, and Maria Under

the Bipartisan Budget Act of 2018 Non-Construction (Admin Supp Clinical Trial Optional) (PA-18-936)

Deadline December 14, 2018


Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional) (PA-18-937)

Deadline February 5, 2019


Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed) (PA-18-939)

Deadline February 16, 2019


Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21

Clinical Trial Optional) (PAR-18-941) – Deadline November 26, 2018


Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01

Clinical Trial Optional) (PAR-18-942) – Deadline November 26, 2018


Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical

Trial Not Allowed) (PAR-18-947) – Deadline November 28, 2018





Melanoma Research Alliance – Deadline for all Established Investigator, Pilot and Young

Investigator Award Proposals – Deadline November 2, 2018


Melanoma Research Alliance – Deadline for ASTRO-MRA Early Career Investigator Proposal

Deadline November 9, 2018



New Clinical Study Opportunities


Please note this is NOT a solicitation for study subjects


Several Pharmaceutical companies are looking for Principal Investigators to participate in the following clinical studies:

  • Head And Neck Squamous Cell Carcinoma
  • Phase 2a Study In Patients With Igan

Phase 3 Study Of APL2 In Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Having A  Sub-Optimal Response To Eculizumab

  • VEGFR Inhibitor- induced Hand Foot Skin Reaction #117716
  • Tumor Sampling/Genome Sequencing
  • Systemic Lupus Erythematosus Study D3465C00001
  • Atopic Dermatitis
  • eSIF Study
  • Phase III for Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary

            Autonomic Failure (Parkinson`s Disease, Pure Autonomic Failure and Multiple System Atrophy).

Please contact Scott Davis at if you would like to receive more information on any

of these studies. The resulting confidentiality and/or clinical study agreement will need to be routed to the

Office of Research Administration.